Advocacy intelligence hub — real-time data for patient organizations
China Immunotech (Beijing) Biotechnology Co., Ltd. — PHASE1
Peking Union Medical College Hospital — PHASE2
Centre Hospitalier Universitaire de Nice — NA
Yihao Wang — PHASE1, PHASE2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — PHASE1
Bing Han — PHASE2
Peking Union Medical College Hospital
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
National Cancer Institute (NCI)
Zhejiang University — EARLY_PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Azacitidine
(AZACITIDINE)Orphan drugstandardDr. Reddy's Laboratories Inc.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine for injection is a pyrimidine nucleoside analog of cytidine. Azacitidine for injection is believed to exert its a...
Azacitidine
(AZACITIDINE FOR)Orphan drugstandardPilnova Pharma Inc
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine is a pyrimidine nucleoside analog of cytidine. Azacitidine is believed to exert its antineoplastic effects by cau...
Reblozyl
(LUSPATERCEPT)Orphan drugstandardCelgene Corporation
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Jun Shi
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Anoop Enjeti
Calvary Mater Newcastle, Edith Street, Waratah, NSW 2298 Australia
Thomas G. Martin, MD
University of California, San Francisco
Hannah Choe, MD
Ohio State University Comprehensive Cancer Center
Stine Ulrik Mikkelsen, MD, PhD
Rigshospitalet, Denmark
View all Myelodysplastic neoplasm with low blasts specialists →